

MISSION

Role Intern in Corporate Finance
Mergers & Acquisitions, Valuation

You will be involved in:
Analysing Specific Sectors
Monitoring Industry Players
Drawing Company Profiles
Writing Pitch Books
Modelling Company Valuations
Writing Info Memos
Preparing Datarooms

Start Date September 2010

Duration 6 months minimum

Bionest Partners is a corporate finance & strategy consultancy boutique specialised in healthcare (Biotechnologies, Pharmaceuticals, Medical Devices, and Health Services)

You will work in a team of 25 FTEs for industrials & funds such as:



PROFIL

Education Top European Business Schools & Universities

Major in Corporate Finance, min. Bac+4
Fluent French and English required
Scientific background is a plus (Pharma / Biotech / Life Sciences...)

Qualities

Strong motivation
Quick learner, initiative spirit, hard worker
Rigour, ability to summarise
Strong Excel & PowerPoint skills
Interest in healthcare and biotechnology sectors

DETAILS

Company

BIONEST PARTNERS
Corporate Finance

Locations















Paris - France

Contact

recruit@bionest.com
Please send CV & Cover Letter
with detailed dates of availability

Financial Conditions

Attractive

<p>2008</p>  <p><i>Has Out-licensed Research L-Asparaginase to</i></p>  <p>Sole Advisor</p>	<p>2008</p>  <p><i>Has Divested MAb Research Business to</i></p>  <p>Sole Advisor</p>	<p>2008</p>  <p><i>Has Out-licensed Preclinical OP-R003</i></p>  <p>Sole Advisor</p>	<p>2007</p>  <p><i>Has Sold Ginkor Fort to</i></p>  <p>Sole Advisor</p>
<p>2008</p>  <p><i>Oncology</i></p>  <p>Assessment of Product Franchise</p>	<p>2008</p>  <p><i>(Financing Round)</i></p> <p><i>Mature Products</i></p> <p>Corporate Valuation</p>	<p>2008</p>  <p><i>(Financing Round)</i></p> <p><i>Oncology</i></p> <p>Corporate Valuation</p>	<p>2008</p>  <p><i>(Out-licensing)</i></p> <p><i>Oncology</i></p> <p>Asset Valuation</p>
<p>2008</p> <p>Leading French Biotech</p> <p><i>Biomanufacturing CMO</i></p> <p>Identification of Potential Targets</p>	<p>2007</p> <p>Leading French Biotech</p> <p><i>Anaesthetics / Intensive Care</i></p> <p>Identification of Potential Targets</p>	<p>2007</p> <p>Adenobio</p> <p><i>(Out-licensing)</i></p> <p><i>Cardiovascular & Dietary Supplements</i></p> <p>Asset Valuation</p>	<p>2007</p>  <p><i>(Financing Round)</i></p> <p><i>Anti-infectious</i></p> <p>Corporate Valuation</p>